HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
Stocks · News reference
Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from